Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinsonâs disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAMRX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAmneal Pharmaceuticals Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 18, 2009
āļāļĩāļāļĩāđāļMr. Chintu Patel
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ8100
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļNov 18
āļāļĩāđāļāļĒāļđāđ400 Crossing Boulevard, 3rd Floor
āđāļĄāļ·āļāļBRIDGEWATER
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Global Select Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ08807
āđāļāļĢāļĻāļąāļāļāđ19089473120
āđāļ§āđāļāđāļāļāđhttps://amneal.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAMRX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 18, 2009
āļāļĩāļāļĩāđāļMr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
Mr. Shlomo Yanai
Independent Director
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Mr. Chirag Patel
President, Co-Chief Executive Officer, Co-Founder, Director
President, Co-Chief Executive Officer, Co-Founder, Director
Mr. Ted Nark
Independent Director
Mr. Paul M. Meister
Independent Chairman of the Board
Independent Chairman of the Board
Mr. John J. Kiely
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
Mr. Shlomo Yanai
Independent Director
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Invesco Pharmaceuticals ETF
SPDR S&P Pharmaceuticals ETF
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
AltShares Event-Driven ETF
First Trust NASDAQ Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF
First Trust Small Cap Growth AlphaDEX Fund
First Trust Small Cap Core Alphadex Fund
Invesco Nasdaq Biotechnology ETF
ProShares Ultra Nasdaq Biotechnology
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Invesco Pharmaceuticals ETF
SPDR S&P Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ2.22%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
āļŠāļąāļāļŠāđāļ§āļ1.57%
AltShares Event-Driven ETF
āļŠāļąāļāļŠāđāļ§āļ1.53%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ0.87%
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ0.61%
First Trust Small Cap Growth AlphaDEX Fund
āļŠāļąāļāļŠāđāļ§āļ0.53%
First Trust Small Cap Core Alphadex Fund
āļŠāļąāļāļŠāđāļ§āļ0.29%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.28%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ0.28%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ